Baseline clinical characteristics
| Variable n (%) | Diabetes IR (n=668) | Diabetes CR (n=757) | Non-diabetes IR (n=1709) | Non-diabetes CR (n=2216) | p Value* | ||||
|---|---|---|---|---|---|---|---|---|---|
| Age, years | 69.1 | (11.9) | 66.4 | (11.5)† | 69.6 | (12.7) | 66.2 | (12.1)‡ | 0.97 |
| Male gender | 441 | (66%) | 499 | (66%) | 1237 | (72%) | 1564 | (71%) | <0.001 |
| Risk score for long-term death | 6.3 | (2.6) | 5.3 | (2.5)‡ | 5.0 | (2.7) | 4.1 | (2.5)‡ | <0.001 |
| Risk score for long-term death/MI | 7.4 | (3.1) | 6.0 | (2.8)‡ | 5.4 | (3.4) | 4.0 | (3.1)‡ | <0.001 |
| Hypertension | 552 | (85%) | 631 | (86%) | 1133 | (70%) | 1438 | (68%) | <0.001 |
| Smoking status | 0.003 | ||||||||
| Never | 237 | (37%) | 271 | (36%) | 607 | (37%) | 732 | (34%) | |
| Former | 305 | (47%) | 357 | (48%) | 713 | (43%) | 960 | (44%) | |
| Current | 102 | (16%) | 117 | (16%) | 343 | (21%) | 477 | (22%) | |
| Hyperlipidaemia | 514 | (83%) | 594 | (83%) | 1119 | (72%) | 1531 | (76%)‡ | <0.001 |
| Body mass index, Kg/m2 | 31.6 | (6.9) | 32.0 | (6.7) | 28.7 | (5.5) | 29.0 | (5.5) | <0.001 |
| History of prior MI | 225 | (34%) | 196 | (26%) | 483 | (29%) | 414 | (19%)‡ | <0.001 |
| Acute coronary syndrome, n | 378 | (57%) | 402 | (54%) | 1136 | (67%) | 1376 | (63%)‡ | <0.001 |
| Canadian Heart Class III, IV | 317 | (47%) | 376 | (50%) | 790 | (46%) | 1138 | (51%) | 0.75 |
| Predominant symptom | <0.001 | ||||||||
| Chest pain | 524 | (78%) | 581 | (77%) | 1448 | (85%) | 1842 | (83%)† | |
| Other | 144 | (22%) | 176 | 23% | 261 | 15% | 374 | 17% | |
| History of CHF | <0.001 | ||||||||
| Never | 439 | (70%) | 596 | (83%) | 1377 | (84%) | 1928 | (90%) | |
| Ever | 192 | (30%) | 125 | (17%) | 263 | (17%) | 205 | (9%) | |
| Most recent MI | <0.001 | ||||||||
| <24 h | 114 | (17%) | 96 | (13%)‡ | 447 | (26%) | 471 | (22%)‡ | |
| 1–7 days | 151 | (23%) | 118 | (16%) | 348 | (21%) | 345 | (16%) | |
| >7 days | 162 | (25%) | 165 | (22%) | 332 | (20%) | 316 | (14%) | |
| Never | 231 | (35%) | 368 | (49%) | 560 | (33%) | 1054 | (48%) | |
| Prior PCI | 148 | (22%) | 196 | (26%) | 279 | (16%) | 443 | (20%)‡ | <0.001 |
| Peripheral vascular disease | 116 | (18%) | 123 | (17%) | 168 | (10%) | 157 | (7%) | <0.001 |
| Cerebrovascular disease | 115 | (18%) | 97 | (13%) | 201 | (12%) | 186 | (9%) | <0.001 |
| Moderate/severe renal disease | 51 | (8%) | 59 | (8%) | 62 | (4%) | 34 | (2%) | <0.001 |
| Chronic obstructive lung disease | 101 | (15%) | 89 | (12%) | 189 | (11%) | 237 | (11%) | 0.012 |
| Peptic ulcer disease | 39 | (6%) | 29 | (4%) | 91 | (5%) | 120 | (6%)‡ | 0.37 |
| Tumour/lymphoma/leukaemia | 103 | (16%) | 88 | (12%) | 244 | (14%) | 265 | (12%) | 0.69 |
| Metastatic cancer | 5 | (1%) | 5 | (1%) | 14 | (1%) | 15 | (1%) | 0.89 |
| Prophylactic IABP | 18 | (3%) | 1 | (0%) | 29 | (2%) | 19 | (1%) | 0.75 |
| LVEF, n (%) | <0.001 | ||||||||
| >40% | 260 | (39%) | 386 | (51%) | 773 | (45%) | 1167 | (53%) | |
| ≤40% | 130 | (19%) | 86 | (11%) | 242 | (14%) | 146 | (7%) | |
| Not available | 278 | (42%) | 285 | (38%) | 694 | (41%) | 903 | (41%) | |
*Overall comparison for all four groups by ANOVA or χ2 test.
†0.01≤p<0.05 for CR vs IR comparison.
‡p<0.01 vs IR for CR vs IR comparison.
ANOVA, analysis of variance; CHF, congestive heart failure; CR, complete revascularisation; IABP, intra-aortic balloon pump; IR, incomplete revascularisation; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.